Captor Therapeutics Spolka Akcyjna Company Description

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases.

The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics.

It has various therapeutic molecules in the preclinical stage. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.

Captor Therapeutics Spolka Akcyjna

Country	Poland
Founded	2015
Industry	Biotechnology
Sector	Healthcare
Employees	91
CEO	Michal Walczak

Contact Details

Address: ul. Dunska 11 Wroclaw, 54-427 Poland
Phone	48 53 786 9089
Website	captortherapeutics.com

Stock Details

Ticker Symbol	CTX
Exchange	Warsaw Stock Exchange
Fiscal Year	January - December
Reporting Currency	PLN
ISIN Number	PLCPTRT00014
SIC Code	2836

Key Executives

Name	Position
Michal Walczak	Chief Executive Officer and Chief Scientific Officer
Sylvain Cottens	Co-Founder and Senior Vice President of Chemistry
Adam Lukojc	Chief Financial Officer
Anna Pawluk	Chief Operating Officer
Tomas Drmota	Chief Technology Officer
Marta Tomaszewska	Vice President of People and Culture
Dr. Thomas Shepherd Ph.D.	Senior Vice President of Strategy
Dr. Robert Dyjas	Head of Medical Affairs and Clinical Development
Dr. Andrew Saunders FFPM, M.D.	Chief Medical Officer
Dr. Anthony Rowen-Brown BSc., Dphil, M.B.A., Ph.D.	Chief Business Officer